ImmunoACT announces partnership with Mango Sciences to bring the world’s first bridge financing plan and value-based offering for CAR-T therapy for cancer patients in India0

• Latest News
• December 3, 2025

Mumbai (Maharashtra) [India], December 2: ImmunoAdoptive Cell Therapy (ImmunoACT), the Mumbai, India-based pioneering research and cell and gene therapy development company, announced a strategic partnership with Mango Sciences, Inc., the Boston, US, and Bengaluru, IN-based data and AI company, to expand access and affordability of ImmunoACT’s NexCAR19TM chimeric antigen receptor T-cell (CAR-T) for leukaemia and